-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $140

Benzinga·02/17/2026 16:08:23
Listen to the news
Truist Securities analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $169 to $140.